Assembly Biosciences Near Breakout; Key Clinical Trials in Focus
AI Prediction of Assembly Biosciences, Inc (ASMB)
Assembly Biosciences, a clinical-stage biotech company focusing on hepatitis B cures, has shown promising developments in its drug pipeline and strategic collaborations. Given the upcoming clinical trial results and potential regulatory milestones, investors may find significant opportunities for growth.
ASMB Report Information
Prediction Date2025-07-03
Close @ Prediction$18.14
Mkt Cap130m
IPO Date2010-12-17
AI-derived Information
Recent News for ASMB
- Dec 23 — GILD Exercises Option to License Assembly Bio's Herpes Programs (Zacks)
- Dec 22 — Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes (Business Wire)
- Dec 8 — Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes (GlobeNewswire)
- Nov 10 — Assembly Biosciences: Q3 Earnings Snapshot (Associated Press Finance)
- Nov 10 — Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates (GlobeNewswire)
- Nov 7 — Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting (GlobeNewswire)
- Nov 5 — Supernus Pharmaceuticals (SUPN) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
- Oct 29 — H.C. Wainwright Reaffirms Buy Rating on Assembly Biosciences, Inc. (ASMB) Amid Promising Trial Data (Insider Monkey)
- Oct 14 — Assembly Biosciences Announces Upcoming Investor Conference Participation (GlobeNewswire)
- Oct 10 — Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe (GlobeNewswire)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.